Analysts expect biote Corp to report Q3 2026 revenue of $53.8 million and a loss per share of $0.05, while the stock currently trades at $7.12, trailing the average analyst price target of $10.00.
Investors are primarily focused on the growth of procedure-related revenue, which serves as the core engine for the company's hormone optimization business.
Recent financial performance has been characterized by steady top-line expansion offset by significant legal expenses and increased investments in practitioner training programs. Shareholders will be looking for management to provide clarity on the long-term margin profile and the status of ongoing clinical expansion initiatives.